Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Objective to evaluate the efficacy and safety of neoadjuvant therapy with Chidamide combined
with chemotherapy for stage II - III triple-negative breast cancer，and to compare the
efficacy and safety of chemotherapy with Chidamide and chemotherapy alone in the neoadjuvant
treatment of stage II - III triple-negative breast cancer
Phase:
N/A
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital